Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pontificia Universidad Catolica de Chile
With
Fundacion Arturo Lopez Perez
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient older than 18 years
CALL score ≥ 9 (progression risk score)
PCR-confirmed COVID-19 infection with equal or less than 7 days of symptoms (or imaging consistent with COVID-19 pneumonia and confirmed COVID-19 contact)
Any symptoms of COVID-19 infection
Admission due to COVID-19 infection
Signed informed consent
ECOG before COVID-19 infection 0-2
You may not be if
PaFi \<200 or mechanical ventilation indication
Clinically relevant co-infection at admission
Pregnancy or lactation
IgA deficiency or IgA nephropathy
Immunoglobulin or plasma administration in the last 60 days
Contraindication to transfusion or previous allergy to blood-derived products
Do-not-resuscitate status
Patients receiving other investigational drug for COVID-19 in a clinical trial
Any condition, that in opinion of the investigator may increase the risk associated with study participation or interfere with the interpretation of study results.
Clareo Health | Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
